Data analysis: the highs and lows of generic-filed IPRs

We reviewed a sub-group of 204 inter partes reviews (IPRs) filed by generic drug companies against pharmaceutical patents to assess Patent Trial and Appeal Board (PTAB) outcomes and key trends in dealing with this technology field. The study captured IPR filings by 14 of the most active generic petitioners among the world’s top-20 generic drug companies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Ex-Simmons head of IP joins Carpmaels & Ransford

Moderna: BioNTech is claiming work ‘it never did’

Siemens ordered to recall mammography device across European countries

MoFo bags IP trial duo with 50 years’ combined experience

Data analysis: the highs and lows of generic-filed IPRs

More on this story

Editor's picks

Editor's picks

More features